艾奥尼斯制药公司宣布,计划独立在美国市场推出其药物Zilganersen。与此同时,美国食品药品监督管理局已将该药物的处方药使用者付费法案目标审评日期设定在9月22日。
艾奥尼斯制药公司宣布,计划独立在美国市场推出其药物Zilganersen。与此同时,美国食品药品监督管理局已将该药物的处方药使用者付费法案目标审评日期设定在9月22日。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.